Supported by the Ministry of Education’s “Top Research Centers in National Key Areas Program,” National Taiwan University (NTU) has inaugurated the AI Top Research Center and the Advanced Biomedical Research Center in 2025. NTU stated that these centers not only echo Taiwan’s urgent needs in frontier technologies and precision medicine, but also demonstrate the university’s commitment to leading Taiwan’s research development in critical fields.

NTU President Wen-Chang Chen said the university will continue leveraging the two major platforms—the AI Top Research Center and the Advanced Biomedical Research Center—to deepen internationally aligned collaboration models and translate research outcomes into real-world impact. These efforts aim to further elevate Taiwan’s position in global technology and healthcare innovation.

The AI Top Research Center is led by Lin-shan Lee, an Academia Sinica Academician and a pioneering figure in speech recognition. He brings together eight internationally influential mid-career and next-generation scholars as the core research team. The center’s roadmap spans four strategic directions: AI applications and ethics education in higher education, trustworthy and explainable AI, next-generation AI models and infrastructure, and multilingual and cross-cultural semantic understanding.

For international collaboration, the center will engage in deep partnerships with leading global institutions such as MIT, Stanford University, Max Planck Institute, RIKEN, and INRIA. It will also establish strategic alliances with globally influential technology companies including NVIDIA, Google DeepMind, Meta AI, Microsoft Research, Amazon AI, and OpenAI.

The Advanced Biomedical Research Center integrates resources across NTU’s College of Medicine, College of Key Technology Research, College of Electrical Engineering and Computer Science, NTU Hospital, and the Genome and Precision Medicine Research Center. With a “bench-to-bedside” focus, the center is committed to cross-disciplinary innovation in precision medicine and biomedical technologies.

Its members include Pan-Chyr Yang, Director of the YongLin Institute of Health at NTU, among others. The three-year research initiative is structured into two main tracks: a Disease Track and an Application Track. Key disease areas include lung cancer, cardiovascular diseases, neurodegeneration, autoimmune disorders, and gut microbiome–related conditions. Application research focuses on high-resolution miniaturized biomedical imaging technologies, AI diagnostic platforms, and multispecific antibody drug development.

Internationally, the center has partnered with the French National Centre for Scientific Research (CNRS) and the National Institute of Health and Medical Research (INSERM) to jointly establish the Taiwan–France Center for Precision Medicine Research.

In terms of industry collaboration, the Quanta Medical Technology Foundation and Scientech Corporation have each pledged annual donations of NT$5 million and NT$10 million, respectively, for five consecutive years to support the center’s research advancement—laying a solid foundation for the development of precision medicine in Taiwan.

Resource: 結合產學資源、與國際接軌 台大成立AI、先進生醫研究中心